Comparative analysis of cell death induction by Taurolidine in different malignant human cancer cell lines

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Chromik, Ansgar M ^a   Daigeler, Adrien ^b   Bulut, Daniel ^a   Flier, Annegret ^a   May, Christina ^a   Harati, Kamran ^a   Roschinsky, Jan ^a   Sülberg, Dominique ^a   Ritter, Peter R ^a   Mittelkötter, Ulrich ^a   Hahn, Stephan A ^c   Uhl, Waldemar ^a  

^a ST JOSEF HOSPITAL   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BUTHIONINE SULFOXIMINE; CASPASE; CASPASE INHIBITOR; LIPOCORTIN 5; PROPIDIUM IODIDE; REACTIVE OXYGEN METABOLITE; TAUROLIDINE; UNCLASSIFIED DRUG; Z VAD; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTATHIONE; TAURINE; THIADIAZINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL STRAIN HT29; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; FIBROSARCOMA; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; LIVER CANCER; PANCREAS CANCER; PRIORITY JOURNAL; STAINING; CELL SURVIVAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; EVALUATION; METABOLISM; NEOPLASM; TUMOR CELL LINE;

ACETYLCYSTEINE; ANTINEOPLASTIC AGENTS; CASPASES; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE; HUMANS; NEOPLASMS; REACTIVE OXYGEN SPECIES; TAURINE; THIADIAZINES;

EID: 77950382454     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-21     Document Type: Article

References (43)

1. Taurolidine peritoneal lavage as prophylaxis against infection after elective colorectal surgery. DM Baker JA Jones JS Nguyen-Van-Tam JH Lloyd DL Morris JB Bourke RJ Steele JD Hardcastle, Br J Surg 1994 81 1054 1056 10.1002/bjs.1800810743 7922063
2. Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients. A Simon RA Ammann G Wiszniewsky U Bode G Fleischhack MM Besuden, BMC Infect Dis 2008 8 102 10.1186/1471-2334-8-102 18664278
3. Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients. M Koldehoff JL Zakrzewski, Int J Antimicrob Agents 2004 24 491 495 10.1016/j.ijantimicag.2004. 06.006 15519483 (Pubitemid 39425163)
4. Taurolidine - a new drug with anti-tumor and anti-angiogenic effects. CA Jacobi C Menenakos C Braumann, Anticancer Drugs 2005 16 917 921 10.1097/01.cad.0000176502.40810.b0 16162968 (Pubitemid 41416082)
5. Effects of increasing doses of a bolus injection and an intravenous long-term therapy of taurolidine on subcutaneous (metastatic) tumor growth in rats. C Braumann M Schoenbeck C Menenakos M Kilian CA Jacobi, Clin Exp Metastasis 2005 22 77 83 10.1007/s10585-005-4695-4 16132581 (Pubitemid 41185864)
6. Synergistic effects in apoptosis induction by taurolidine and TRAIL in HCT-15 colon carcinoma cells. AM Chromik A Daigeler C Hilgert D Bulut A Geisler V Liu JM Otte W Uhl U Mittelkotter, J Invest Surg 2007 20 339 348 10.1080/08941930701772157 18097875
7. Synergistic apoptotic effects of taurolidine and TRAIL on squamous carcinoma cells of the esophagus. A Daigeler AM Chromik A Geisler D Bulut C Hilgert A Krieg L Klein-Hitpass M Lehnhardt W Uhl U Mittelkötter, Int J Oncol 2008 32 1205 1220 10.3892/ijo-32-6-1205 18497982
8. The effect of taurolidine on brain tumor cells. R Stendel G Stoltenburg-Didinger CL Al Keikh M Wattrodt M Brock, Anticancer Res 2002 22 809 814 12014655 (Pubitemid 34475233)
9. The antibacterial substance taurolidine exhibits anti-neoplastic action based on a mixed type of programmed cell death. R Stendel HR Biefer GM Dekany H Kubota C Munz S Wang H Mohler Y Yonekawa K Frei, Autophagy 2009 5 194 210 10.4161/auto.5.2.7404 19066471
10. The tumor suppressive reagent taurolidine inhibits growth of malignant melanoma - a mouse model. C Braumann CA Jacobi S Rogalla C Menenakos K Fuehrer U Trefzer M Hofmann, J Surg Res 2007 143 372 378 10.1016/j.jss.2007.01.041 17612567 (Pubitemid 350101573)
11. Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins. BS Sun JH Wang LL Liu SL Gong HP Redmond, J Surg Oncol 2007 96 241 248 10.1002/jso.20827 17469118
12. Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma. I Opitz B Sigrist S Hillinger D Lardinois R Stahel W Weder S Hopkins-Donaldson, Lung Cancer 2007 56 327 336 10.1016/j.lungcan.2007.01.024 17383050 (Pubitemid 46679090)
13. Taurolidine and oxidative stress: a rationale for local treatment of mesothelioma. N Aceto P Bertino D Barbone G Tassi L Manzo C Porta L Mutti G Gaudino, Eur Respir J 2009 34 1399 1407 10.1183/09031936.00102308 19460788
14. TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma. A Daigeler C Brenzel D Bulut A Geisler C Hilgert M Lehnhardt HU Steinau A Flier L Steinstraesser L Klein-Hitpass, et al. J Exp Clin Cancer Res 2008 27 82 10.1186/1756-9966-27-82 19077262
15. Taurolidine: a novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines. DK Walters R Muff B Langsam P Gruber W Born B Fuchs, Invest New Drugs 2007 25 305 312 10.1007/s10637-007-9052-9 17458504 (Pubitemid 46944855)
16. Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case. C Braumann G Winkler P Rogalla C Menenakos CA Jacobi, World J Surg Oncol 2006 4 34 10.1186/1477-7819-4- 34 16796759 (Pubitemid 44262718)
17. Treatment of glioblastoma with intravenous taurolidine. First clinical experience. R Stendel T Picht A Schilling J Heidenreich C Loddenkemper W Janisch M Brock, Anticancer Res 2004 24 1143 1147 15154639 (Pubitemid 38624954)
18. Pharmacokinetics of taurolidine following repeated intravenous infusions measured by HPLC-ESI-MS/MS of the derivatives taurultame and taurinamide in glioblastoma patients. R Stendel L Scheurer K Schlatterer U Stalder RW Pfirrmann I Fiss H Mohler L Bigler, Clin Pharmacokinet 2007 46 513 524 10.2165/00003088-200746060-00005 17518510 (Pubitemid 46827860)
19. The pharmacokinetics of taurolidine metabolites in healthy volunteers. L Gong HE Greenberg JL Perhach SA Waldman WK Kraft, J Clin Pharmacol 2007 47 697 703 10.1177/0091270007299929 17395893 (Pubitemid 46800427)
20. Cell death. RS Hotchkiss A Strasser JE McDunn PE Swanson, N Engl J Med 2009 361 1570 1583 10.1056/NEJMra0901217 19828534
21. Apoptosis effector mechanisms: a requiem performed in different keys. N Hail Jr BZ Carter M Konopleva M Andreeff, Apoptosis 2006 11 889 904 10.1007/s10495-006-6712-8 16547589 (Pubitemid 43880261)
22. Mechanistic and antineoplastic evaluation of taurolidine in the DU145 model of human prostate cancer. JW Darnowski FA Goulette LP Cousens D Chatterjee P Calabresi, Cancer Chemother Pharmacol 2004 54 249 258 10.1007/s00280-004- 0806-1 15173956 (Pubitemid 39141742)
23. The antibacterial drug taurolidine induces apoptosis by a mitochondrial cytochrome c-dependent mechanism. Z Han I Ribbizi P Pantazis J Wyche J Darnowski P Calabresi, Anticancer Res 2002 22 1959 1964 12174870
24. Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vascular endothelial growth factor production by taurolidine. R Rodak H Kubota H Ishihara HP Eugster D Konu H Mohler Y Yonekawa K Frei, J Neurosurg 2005 102 1055 1068 10.3171/jns.2005.102.6.1055 16028765 (Pubitemid 43193975)
25. Enhancement of Fas-ligand-mediated programmed cell death by taurolidine. R Stendel L Scheurer G Stoltenburg-Didinger M Brock H Mohler, Anticancer Res 2003 23 2309 2314 12894508 (Pubitemid 36897096)
26. Synergistic apoptotic effects of taurolidine and TRAIL on squamous carcinoma cells of the esophagus. A Daigeler AM Chromik A Geisler D Bulut C Hilgert A Krieg L Klein-Hitpass M Lehnhardt W Uhl U Mittelkotter, Int J Oncol 2008 32 6 1205 20 10.3892/ijo-32-6-1205 18497982
27. Taurolidine inhibits tumor cell growth in vitro and in vivo. M McCourt JH Wang S Sookhai HP Redmond, Ann Surg Oncol 2000 7 685 691 10.1007/s10434-000- 0685-6 11034247
28. The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma. L Nici B Monfils P Calabresi, Clin Cancer Res 2004 10 7655 7661 10.1158/1078-0432.CCR-0196-03 15569998 (Pubitemid 39557529)
29. Instillation of taurolidine/heparin after laparotomy reduces intraperitoneal tumour growth in a colon cancer rat model. I Opitz H Van der Veen N Witte C Braumann JM Mueller CA Jacobi, Eur Surg Res 2007 39 129 135 10.1159/000100109 17337889 (Pubitemid 46633173)
30. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). OW Griffith A Meister, J Biol Chem 1979 254 7558 7560 38242
31. Glutathione in cancer biology and therapy. JM Estrela A Ortega E Obrador, Crit Rev Clin Lab Sci 2006 43 143 181 10.1080/10408360500523878 16517421 (Pubitemid 43860449)
32. The tumor-suppressive reagent taurolidine is an inhibitor of protein biosynthesis. C Braumann W Henke CA Jacobi W Dubiel, Int J Cancer 2004 112 225 230 10.1002/ijc.20393 15352034 (Pubitemid 39244362)
33. Synergistic effects in apoptosis induction by taurolidine and TRAIL in HCT-15 colon carcinoma cells. AM Chromik A Daigeler C Hilgert D Bulut A Geisler V Liu JM Otte W Uhl U Mittelkötter, J of Investigative Surgery 2007 20 339 348 10.1080/08941930701772157
34. TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma. A Daigeler C Brenzel D Bulut A Geisler C Hilgert M Lehnhardt HU Steinau A Flier L Steinstraesser L Klein-Hitpass, et al. J Exp Clin Cancer Res 2008 27 82 10.1186/1756-9966-27-82 19077262
35. Divergent effects of taurolidine as potential anti-neoplastic agent: Inhibition of bladder carcinoma cells in vitro and promotion of bladder tumor in vivo. C Abramjuk M Bueschges J Schnorr K Jung A Staack M Lein, Oncol Rep 2009 22 409 414 19578784
36. Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vascular endothelial growth factor production by taurolidine. R Rodak H Kubota H Ishihara H-P Eugster D Könü H Möhler Y Yonekawa K Frei, J Neurosurg 2005 102 1055 1068 10.3171/jns.2005.102.6.1055 16028765 (Pubitemid 43193975)
37. Cancer cell killing via ROS: to increase or decrease, that is the question. J Wang J Yi, Cancer Biol Ther 2008 7 1875 1884 18981733
38. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. KA Conklin, Integr Cancer Ther 2004 3 294 300 10.1177/1534735404270335 15523100 (Pubitemid 39552423)
39. Oxidative stress and apoptosis: a new treatment paradigm in cancer. RH Engel AM Evens, Front Biosci 2006 11 300 312 10.2741/1798 16146732
40. Oxidative stress and apoptosis: impact on cancer therapy. T Ozben, J Pharm Sci 2007 96 2181 2196 10.1002/jps.20874 17593552 (Pubitemid 47477879)
41. Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. DW Chan VW Liu GS Tsao KM Yao T Furukawa KK Chan HY Ngan, Carcinogenesis 2008 29 1742 1750 10.1093/carcin/bgn167 18632752
42. Caspase-independent pathways of programmed cell death: the unraveling of new targets of cancer therapy? C Constantinou KA Papas AI Constantinou, Curr Cancer Drug Targets 2009 9 717 728 10.2174/156800909789271512 19754356
43. Apoptosis and non-apoptotic deaths in cancer development and treatment response. EC de Bruin JP Medema, Cancer Treat Rev 2008 34 737 749 10.1016/j.ctrv.2008.07.001 18722718